Clinical Trial Update: Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating metabolic biomarkers to predict response to neoadjuvant immunotherapy in Non-Small Cell Lung Cancer; study status is recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Hospital das Clínicas de Ribeirão Preto | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING